Experienced in Metatarsalgia

Dr. Michael R. Savona

Internal Medicine
1830 Wells St, Suite 102, 
Wailuku, HI 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Metatarsalgia
1830 Wells St, Suite 102, 
Wailuku, HI 
OverviewInsuranceLocationsClinical Research

Overview

Michael Savona is a primary care provider, practicing in Internal Medicine in Wailuku, Hawaii. Dr. Savona is rated as an Experienced provider by MediFind in the treatment of Metatarsalgia. His top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Leukemia, and Chronic Myelomonocytic Leukemia (CMML).

His clinical research consists of co-authoring 175 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Licenses
Internal Medicine in HI
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Hawaii Medical Assurance Association
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

1830 Wells St, Suite 102, Wailuku, HI 96793

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Multi-phase, Pharmacokinetics, Safety, and Efficacy Study of ASTX030 (Azacitidine and Cedazuridine) as Monotherapy in Subjects With Myeloid Neoplasm or in Combination With Venetoclax in Subjects With AML (AZTOUND Study)
A Multi-phase, Pharmacokinetics, Safety, and Efficacy Study of ASTX030 (Azacitidine and Cedazuridine) as Monotherapy in Subjects With Myeloid Neoplasm or in Combination With Venetoclax in Subjects With AML (AZTOUND Study)
Enrollment Status: Recruiting
Publish Date: October 02, 2025
Intervention Type: Drug
Study Drugs: Azacitidine, Cedazuridine
Study Phase: Phase 2/Phase 3
Clinical Evaluation of ASTX727 in Combination With Venetoclax All-Oral Therapy vs Standard of Care Cytarabine and Anthracycline Induction Chemotherapy for Younger FLT3WT Patients With ELN High- Risk Acute Myeloid Leukemia
Clinical Evaluation of ASTX727 in Combination With Venetoclax All-Oral Therapy vs Standard of Care Cytarabine and Anthracycline Induction Chemotherapy for Younger FLT3WT Patients With ELN High- Risk Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: May 22, 2025
Intervention Type: Drug, Procedure
Study Drugs: Cytarabine, Daunorubicin, Decitabine, Cedazuridine, Venetoclax
Study Phase: Phase 1/Phase 2
A Phase I/II Study of SEL24 in Patients With Acute Myeloid Leukemia
A Phase I/II Study of SEL24 in Patients With Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: April 29, 2025
Intervention Type: Drug
Study Drugs: SEL24, MEN1703
Study Phase: Phase 1/Phase 2
Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML
Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML
Enrollment Status: Completed
Publish Date: April 15, 2025
Intervention Type: Drug
Study Drugs: Cytarabine, Vosaroxin
Study Phase: Phase 2
A Phase II Trial of Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors
A Phase II Trial of Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors
Enrollment Status: Completed
Publish Date: November 04, 2024
Intervention Type: Drug, Procedure
Study Drugs: Azacitidine, Pevonedistat
Study Phase: Phase 2
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drugs: Cedazuridine, Decitabine
Study Phase: Phase 3
A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 With Oral Decitabine in Subjects With Myelodysplastic Syndromes (MDS)
A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 With Oral Decitabine in Subjects With Myelodysplastic Syndromes (MDS)
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Dose Escalation and Expansion Study of TGR-1202 + Ruxolitinib in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (PPV-MF), Post-Essential Thrombocythemia MF (PET-MF), MDS/MPN, or Polycythemia Vera Resistant to Hydroxyurea
A Phase 1 Dose Escalation and Expansion Study of TGR-1202 + Ruxolitinib in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (PPV-MF), Post-Essential Thrombocythemia MF (PET-MF), MDS/MPN, or Polycythemia Vera Resistant to Hydroxyurea
Enrollment Status: Completed
Publish Date: June 27, 2024
Intervention Type: Drug
Study Drugs: TGR-1202 PI3K Delta Inhibitor, Ruxolitinib
Study Phase: Phase 1
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: December 08, 2021
Intervention Type: Drug
Study Drugs: INCB053914, I-DAC (Intermediate Dose Cytarabine), Azacitidine, Ruxolitinib
Study Phase: Phase 1/Phase 2
A Phase 2 Dose-Escalation Study of AEB1102 (Co-ArgI-PEG) in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Refractory to Hypomethylating Agents
A Phase 2 Dose-Escalation Study of AEB1102 (Co-ArgI-PEG) in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Refractory to Hypomethylating Agents
Enrollment Status: Completed
Publish Date: October 17, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

175 Total Publications

A 30-gene classifier distinguishes low-risk MDS HSPCs from healthy HSPCs.
A 30-gene classifier distinguishes low-risk MDS HSPCs from healthy HSPCs.
Journal: Experimental hematology
Published: June 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Savona's expertise for a condition
ConditionClose
    View All 40 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile